Imaging-Guided Gene Therapy of Experimental Gliomas

Andreas H. Jacobs, Maria Adele Rueger, Alexandra Winkeler, Hongfeng Li, Stefan Vollmar, Yannic Waerzeggers, Benedikt Rueckriem, Christiane Kummer, Claus Dittmar, Markus Klein, Michael T. Heneka, Ulrich Herrlinger, Cornel Fraefel, Rudolf Graf, Klaus Wienhard, and Wolf-Dieter Heiss

Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research, Center for Molecular Medicine, and Department of Neurology, University of Cologne, Cologne, Germany

Abstract

To further develop gene therapy for patients with glioblastomas, an experimental gene therapy protocol was established comprising a series of imaging parameters for (i) noninvasive assessment of viable target tissue followed by (ii) targeted application of herpes simplex virus type 1 (HSV-1) amplicon vectors and (iii) quantification of treatment effects by imaging. We show that viable target tissue amenable for application of gene therapy vectors can be identified by multitracer positron emission tomography (PET) using 2-[18F]-fluoro-2-deoxy-D-glucose, methyl-[1-14C]-1-methionine, or 3’-deoxy-3’-[18F]-fluoro-D-thymidine ([18F]FLT). Targeted application of HSV-1 amplicon vectors containing two therapeutic genes with synergistic antitumor activity (Escherichia coli cytosome deaminase, cd, and mutated HSV-1 thymidine kinase, tk39, fused to green fluorescent protein gene, gfp) leads to an overall response rate of 68%, with 18% complete responses and 50% partial responses. Most importantly, we show that the “tissue dose” of HSV-1 amplicon vector–mediated gene expression can be noninvasively assessed by 9-([4-18F]-fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) PET. Therapeutic effects could be monitored by PET with significant differences in [18F]FLT accumulation in all positive control tumors and 72% in vivo transduced tumors (P = 0.01) as early as 4 days after prodrug therapy. For all stably and in vivo transduced tumors, cdIRES(tk39)gfp gene expression as measured by [18F]FHBG-PET correlated with therapeutic efficiency as measured by [18F]FLT-PET. These data indicate that imaging-guided vector application with determination of tissue dose of vector-mediated gene expression and correlation to induced therapeutic effect using multimodal imaging is feasible. This strategy will help in the development of safe and efficient gene therapy protocols for clinical application. [Cancer Res 2007;67(4):1706–15]

Introduction

Gliomas are the most common primary intracranial neoplasms, and ~50% of all gliomas are glioblastomas, the most fatal primary brain neoplasm (1, 2). In view of the high incidence (10–15 per 100,000) and poor prognosis of malignant brain tumors treated with conventional therapies, such as surgery, chemotherapy, brachytherapy, and radiotherapy (3), research focusing on the development of clinically effective alternative therapies such as gene therapy is of utmost importance. Localized transduction of brain tumor cells with therapeutic genes may influence their biological properties by rendering them sensitive to prodrugs, altering the expression of cell cycle regulating proteins, inhibiting angiogenesis, stimulating the immune response, or triggering apoptosis. The helper virus–free herpes simplex virus type 1 (HSV-1) amplicon has been shown to be a safe and efficient vector system in culture and in vivo to transduce various central nervous system (CNS)–derived cells including human gliomas (4–8). Clinical studies revealed that a gene therapy approach as an adjuvant to the surgical resection of recurrent high-grade gliomas can be done safely, although clinical responses were observed in only a few patients with small brain tumors (9–14). The lack of therapeutic efficiency of replication-deficient vector systems in clinical settings may be due to insufficient distribution of vector particles throughout the tumor and heterogeneity of tumor tissue with ineffective transduction of proliferating tumor cells. Therefore, further development of clinically valuable gene therapy protocols for use in patients is an important but also a challenging issue, according to experience. To address these challenges, it is important to develop assays that allow (i) a noninvasive determination of viable target tissue, which might benefit from a biological treatment paradigm, such as gene therapy, as well as assays (ii) for the assessment of the transduced “tissue dose” of a therapeutic gene in patients in vivo. Therefore, one important issue for making gene therapy applicable to patients with brain tumors is the establishment of gene therapy protocols, which contain molecular imaging technology including the assessment of endogenous gene expression as marker for viable and proliferating tumor and the noninvasive monitoring of the location, magnitude, and duration of vector-mediated gene expression in vivo (7, 15, 16). Previously, we and others have shown the in vivo functionality of various gene coexpression constructs based on the internal ribosome entry site (IRES) element serving for the proportional coexpression of a marker gene that can be imaged and a proportionally coexpressed therapeutic gene (7, 17, 18). In the present study, we are using a vector proportionally coexpressing Escherichia coli cytosome deaminase (cd) as therapeutic gene, HSV-1-tk39 as positron emission tomography (PET) marker as well as therapeutic gene, and green fluorescent protein gene (gfp) fused to HSV-1-tk39 (19) as cell culture marker gene. The combination of the transgenes cd and HSV-1-tk39, which encode prodrug-activating enzymes, serves synergistic antitumor activity (20). We show that (i) identification of target tissue, (ii) imaging-guided vector application, (iii) determination of the tissue dose of vector-mediated gene expression, and (iv) correlation to the induced therapeutic effect are feasible.

Note: A.H. Jacobs and M.A. Rueger contributed equally to this work.
Materials and Methods

Cells. Rat F98 and RG2 glioma cells, human GL36dEGFR glioma cells (kind gift of Dr. David Louis, Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, MA), and human U87dEGFR glioma cells (kind gift of Dr. H-J. Su Huang, Ludwig Institute for Cancer Research, San Diego, CA) were grown as monolayers in DMEM (Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Roche Diagnostics, Mannheim, Germany) and 100 units/mL penicillin and 100 μg/mL streptomycin (Life Technologies) at 37°C in a 5% CO2/95% air atmosphere.

HSV-1 amplicon vector. The HSV-1 amplicon backbone pHSV-GN (kind gift of Dr. Xandra Breakefield, Neurogenetics Unit, Massachusetts General Hospital, Boston, MA; refs. 4, 5) was used to create the coexpression cassette containing cd, tk39, and gfp genes as previously described (7). Amplicon plasmid was packaged helper virus–free as previously described to generate HSV-1-cd/tk39/gfp amplicon vector (HSV-CITG; ref. 7). Purified vector stocks were titrated (transducing units per milliliter) on Gli36dEGFR cells by infecting confluent monolayers in 24-well plates (Falcon, Becton Dickinson GmbH, Heidelberg, Germany) and counting GFP-positive cells 24 h after infection (7). Concentrated virus stocks (1 x 10^8 transducing units/mL) were stored at −80°C for further use.

Transduction of tumor cell lines. To generate positive control tumors, a retroviral vector encoding the CITG coexpression construct was engineered in the pBABE puro Moloney murine leukemia virus–based vector backbone (kind gift of Dr. Miguel Sena-Esteves, Neurogenetics Unit.


Table 1. Radiotracer uptake in viable and necrotic tumor, as well as in various organs, obtained from rats and mice bearing s.c. rat F98 and RG2 gliomas and human Gli36dEGFR and U87dEGFR gliomas

<table>
<thead>
<tr>
<th>Tumors</th>
<th>FDG (ROI/BG)</th>
<th>FLT (ROI/BG)</th>
<th>MET (ROI/BG)</th>
<th>FDG (%ID/g)</th>
<th>FLT (%ID/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F98</td>
<td>6.39 ± 3.30</td>
<td>4.02 ± 2.46</td>
<td>3.66 ± 1.25</td>
<td>1.17 ± 0.06</td>
<td>0.90 ± 0.34</td>
</tr>
<tr>
<td>Rim</td>
<td>1.91 ± 0.49</td>
<td>0.63 ± 0.05</td>
<td>0.30 ± 0.17</td>
<td>-0.12 ± 0.02</td>
<td></td>
</tr>
<tr>
<td>Necrosis</td>
<td>2.04 ± 0.22</td>
<td>2.59 ± 0.00</td>
<td>0.40 ± 0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U87dEGFR</td>
<td>3.95 ± 1.75</td>
<td>2.21 ± 0.23</td>
<td>3.86 ± 0.45</td>
<td>0.27 ± 0.09</td>
<td></td>
</tr>
<tr>
<td>Gli36dEGFR</td>
<td>2.79 ± 0.81</td>
<td>2.38 ± 0.40</td>
<td>2.62 ± 0.15</td>
<td>1.72 ± 1.11</td>
<td></td>
</tr>
<tr>
<td>Rim</td>
<td>3.43 ± 0.13</td>
<td>4.17 ± 0.22</td>
<td>0.28 ± 0.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Necrosis</td>
<td>1.16 ± 0.29</td>
<td>4.05 ± 0.00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Organs</th>
<th>FDG (ROI/BG)</th>
<th>FLT (ROI/BG)</th>
<th>MET (ROI/BG)</th>
<th>FDG (%ID/g)</th>
<th>FLT (%ID/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>2.88 ± 1.27</td>
<td>0.30 ± 0.07</td>
<td>1.29 ± 0.46</td>
<td>1.24 ± 0.83</td>
<td>-0.22 ± 0.06</td>
</tr>
<tr>
<td>Kidney</td>
<td>7.21 ± 6.87</td>
<td>9.97 ± 6.32</td>
<td>5.35 ± 1.57</td>
<td>2.90 ± 1.33</td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td>37.62 ± 28.35</td>
<td>20.73 ± 11.31</td>
<td>8.32 ± 2.75</td>
<td>10.56 ± 2.17</td>
<td></td>
</tr>
<tr>
<td>Intestine</td>
<td>1.69 ± 0.91</td>
<td>2.61 ± 0.26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>3.29 ± 1.00</td>
<td>12.01 ± 2.70</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>5.69 ± 1.77</td>
<td>5.26 ± 0.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary glands</td>
<td>3.26 ± 0.30</td>
<td>5.26 ± 0.30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone</td>
<td>3.26 ± 0.30</td>
<td>5.26 ± 0.30</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ROI, region of interest; BG, background.

Massachusetts General Hospital, Boston, MA as previously described (7), including an exchange of the puromycin to the neomycin resistance gene. Thereafter, Gli36dEGFR cells were exposed to retrovirus-containing medium in the presence of polybrene (8 μg/mL) for 8 h. GPP-positive Gli36dEGFR-CITG cells were selected under the presence of 1 mg/mL neomycin for 4 weeks. To generate a tumor clone with a defined level of CITG expression, the mixed cell population was sorted by means of fluorescence-activated cell sorting on a FACStar+ (Becton Dickinson). A Gli36dEGFR-CITG clone with high level of GFP expression was propagated for further use.

Animal experiments. All animal procedures were in accordance with the German Laws for Animal Protection and were approved by the local animal care committee and the Bezirksregierung Köln.

Identification and characterization of target tissue by multiparameter PET. In a first set of experiments, various glioma cell lines (rat F98 and RG2 glioma, human Gli36dEGFR and U87dEGFR glioma) were implanted s.c. into nude rats (n = 12) and nude mice (n = 8) creating three to four tumors per animal, as previously described (7), to establish the noninvasive identification of target tissue. Tumors were grown to various sizes and multiparameter PET imaging was done (see below) with subsequent therapeutic i.p. injection of prodrugs, which were applied daily for 14 days (ganciclovir 25 mg/kg, Cyamene, Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany) and 5-fluorocytosine 500 mg/kg (Ancotil, ICN Pharmaceuticals Germany GmbH, Frankfurt, Germany).

Volumetry. Tumor sizes were measured twice a week with calipers. For each tumor, a growth curve was fitted and its slope calculated using linear regression analysis. Growth slopes of in vivo transduced tumors and of positive control tumors were related to slopes of respective negative controls individually. A ratio between in vivo transduced tumor and negative controls of < 1 indicated a decelerated growth of transduced tumor and thus a response to therapy. Tumors responding to therapy were further classified as complete responders (tumor disappeared completely) and partial responders (decelerated growth).

Radiosynthetics. [18F]FLT was synthesized according to the method of Manullia et al. (21, 22). In brief, no-carrier-added [18F]FLT was produced by nucleophilic substitution using 2,3-anhydro-5′-O-(4,4′-dimethoxytrityl)-thymidine as precursor with a FLT synthesis module (Nuclear Interface, Muenster, Germany). [18F]Fluoride was produced at the cyclotron (MC 17, Scandinomix, Sweden) via the 18O(p,n)18F reaction by bombardment of 95% enriched 18O2/H2O with 17-MeV protons. The no-carrier-added [18F]fluoride (10–30 GBq) was used for routine. The dry [18F]fluoride/ion/K2CO3/K22.2 was obtained from drying kryptofix 2.2.2 (20 mg, 0.53 mmol) dissolved in 1.5-mL acetonitrile and 20-μL 1 N potassium carbonate. Ten milligrams of precursor dissolved in 0.8-mL DMSO were added to the residue and heated to 160°C for 10 min. The hydrolysis was followed with the addition of 0.3-mL 1 N HCl under 130°C for 5 min. After cooling to 30°C, 0.5-mL 0.5 N Na2CO3 was added to the reaction solution, which was first passed through a Sep-Pak cartridge (A–N) to remove kryptofix 2.2.2 and unreacted fluoride, and the Sep-Pak was washed with 0.5-mL high-performance liquid chromatography solvent (10% ethanol in water). Finally, the effluent was automatically injected onto a semipreparative column [synthesis module: Phenomenex Luna C-18(2) 5 μm, 250 × 10 mm; precolumn: Phenomenex Luna C-18(2) 5 μm, 50 × 10 mm] for high-performance liquid chromatography purification. The no-carrier-added

Cancer Res 2007; 67: (4). February 15, 2007 1708 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on December 5, 2021. © 2007 American Association for Cancer Research.
[18F]FLT (10–40 mCi) was collected using 10% (FLT) ethanol in water as the mobile phase at a flow rate of 5.5 mL/min. [18F]FDG (23), [11C]MET (24), and [18F]FHBG (7) were produced as previously described.

Multimodal imaging. T1-weighted magnetic resonance images for localization of tumors were obtained in the second set of experimental animals (n = 22 nude mice) on a 1.5-T Philips Gyroscan Intera before in vivo transduction. PET imaging was done in all animals from both sets of experiments using either a high-resolution research tomograph (ECAT HRRT, CTI/Siemens PET Systems, Knoxville, TN; 207 image planes; spatial resolution of 2.0-mm full width at the half maximum at the center of the field of view) or a microPET (Concorde Microsystems, Inc., Knoxville, TN; 63 image planes; 2.0-mm full width at the half maximum). Radiotracer was administered i.v. (tail vein) into experimental animals with the following doses: no-carrier-added [18F]FDG, 200 μCi/mouse, 400 μCi/rat; no-carrier-added [11C]MET, 400 μCi/mouse, 800 μCi/rat; no-carrier-added [18F]FLT, 250 μCi/mouse, 500 μCi/rat; no-carrier-added [18F]FHBG, 300 μCi/mouse. Emission scans (duration, 30 min) were obtained starting at 40 min ([18F]FDG), 20 min ([11C]MET), 30 min ([18F]FLT), 20 to 120 min (early), and >120 min (late; [18F]FHBG) after tracer application. Maximum a posteriori reconstruction of microPET images was done without scatter and attenuation correction. For quantification of images, a reference standard sample of radiotracer was

![Figure 2. Multimodal imaging and image validation.](https://www.aacrjournals.org/doi/10.1158/0008-5472.CAN-06-1755)

**Figure 2.** Multimodal imaging and image validation. A, experimental protocol for identification of viable target tissue and assessment of vector-mediated gene expression in vivo in a mouse model with three s.c. gliomas. **Row 1,** localization of tumors is displayed by MRI. **Row 2,** the viable target tissue is displayed by [18F]FDG-PET; note the signs of necrosis in the lateral portion of the left-sided tumor (arrow). **Row 3** and **4,** following vector application into the medial viable portion of the tumor (arrow), the tissue dose of vector-mediated gene expression is quantified by [18F]FHBG-PET. **Row 3,** an image acquired early after tracer injection, which is used for coregistration; **row 4,** a late image with specific tracer accumulation in the tumor that is used for quantification. B, good colocalization of the expression of both genetic components of the tkgfp fusion construct by thymidine kinase immunohistochemistry and GFP fluorescence microscopy in a tumor that had been injected with tkgfp-expressing HSV-1 amplicon vectors and imaged by [18F]FHBG-PET.
placed within the field of view of the PET scanner. To allow image coregistration, a newly developed software was used allowing for fast automated coregistration of multimodal imaging data as previously described (VINCI; ref. 25). Data evaluation was based on a region of interest analysis of PET images to determine maximal radioactivity concentrations within tumors. After background (mediastinum) subtraction, data were decay corrected and divided by the total injected dose to represent percentage injected dose per gram (%ID/g).

As gene therapy vectors have to be applied into viable tumor tissue to ensure expression of therapeutic genes, a protocol for acquisition of a series of multimodal images was established, which allows identification of viable target tissue before the initiation of gene therapy using $^{[18F]}$FDG-PET, $^{[11C]}$MET-PET, or $^{[18F]}$FLT-PET. The respective images were coregistered to magnetic resonance images and used for targeted vector application. Following the injection of HSV-1-cdIRE$^{Stk39gfp}$ amplicons, vector-mediated gene expression in vivo was analyzed by the use of the PET-marker gene tk$^{39}$ and its specific tracer $^{[18F]}$FHBG (26, 27). $^{[18F]}$FHBG-PET images acquired early after tracer injection was used for coregistration with the other imaging modalities due to high background of untrapped $^{[18F]}$FHBG. Repeat imaging later than 120 min after $^{[18F]}$FHBG injection was used to evaluate specific $^{[18F]}$FHBG accumulation in transduced tumor portions to ensure quantification of the tissue dose of vector-mediated gene expression (in %ID/g). Moreover, $^{[18F]}$FLT-PET was done as baseline evaluation before in vivo transduction and as therapy monitoring after 1 week of therapy. Therapeutic efficiency was quantified by the difference of $^{[18F]}$FLT accumulation (in %ID/g) before and after therapy (AFLT).

**Tissue sampling and histology.** After the last PET measurements, animals were killed and s.c. tumors were extracted rapidly. After fixation (4% paraformaldehyde, 4°C, 24 h), tumors were embedded in tissue-freezing medium (Jung, Nussloch, Germany) and 20-μm frozen sections were prepared along the transaxial plane relative to the tumor position in the animal. H&E staining on the tissue was done according to standard protocols. Image validation on tumor tissue sections, which has been transduced by tk$^{gfp}$-expressing HSV-1 amplicon vectors, has been done as previously described (7, 28).

**Statistics.** Descriptive statistics and regression analysis were done with Microsoft Excel 2002 (Microsoft Corp., Redmond, WA). Student’s $t$ test was done with SigmaStat 3.0 (SPSS, Inc., Chicago, IL); statistical significance was set at $P < 0.05$.

**Results**

Identification of target tissue for gene therapy is possible by multitracer PET. To validate the feasibility of PET for the identification of viable target tissue, which would be amenable for the local application of gene therapy vectors, in the first set of experiments, tumors growing s.c. in nude rats ($n = 12$) and nude mice ($n = 8$) were visualized by multimodal PET and assessed with respect to the different characteristics of radiotracer uptake within the tumor. Three radiotracers were used, of which two have routine clinical application in patients with gliomas ($^{[18F]}$FDG and $^{[11C]}$MET) and one is known to assess tumor proliferation ($^{[18F]}$FLT). $^{[18F]}$FDG as a surrogate marker for cellular density, $^{[11C]}$MET as a surrogate marker for neovascularization, and $^{[18F]}$FLT as a surrogate marker for proliferative activity displayed homogeneous uptake in small tumors and heterogeneous uptake in larger tumors (Fig. 1A). In the latter, no radiotracer uptake occurred in the central part of the tumors indicative of central necrosis. For image validation, transaxial PET images were coregistered with histology showing a correlation between the lack of tracer accumulation and the histologic signs of necrosis, whereas positive tracer accumulation correlated with viable tumor tissue (Fig. 1B). Radiotracer distribution in viable tumor tissue and necrosis for the different tumor types and in various organs are depicted in Table 1. Tumor-to-background ratios ranged from 1.9 to 8.0 in viable tumor tissue and from 0.4 to 1.2 in necrosis. As an indication of the mode of excretion, $^{[18F]}$FDG and $^{[18F]}$FLT showed substantial uptake in kidney and bladder, and $^{[11C]}$MET accumulation was highest in the liver (Fig. 1A).

**Imaging-guided vector application is feasible.** To enable targeted application of vector particles into viable tumor tissue, image-guided vector application was done as depicted in Fig. 2A with (i) magnetic resonance imaging (MRI) for localization of tumor; (ii) $^{[18F]}$FDG-PET for identification of viable target tissue; (iii) early $^{[18F]}$FHBG-PET for coregistration; and (iv) late $^{[18F]}$FHBG-PET for determination of the total tissue dose of vector-mediated gene expression. Mean cdIRE$^{Stk39gfp}$ expression, as measured by $^{[18F]}$FHBG accumulation, was $1.22 \pm 0.83$ %ID/g for stably transduced positive control tumors and mean transduction efficiency

![Figure 3](https://example.com/figure3.png)
of in vivo transduced tumors was 0.37 ± 0.30% ID/g. For image validation, thymidine kinase immunohistochemistry and GFP fluorescence microscopy have been done on tumors that had been imaged by $[^{18}F]$FHBG-PET after transduction with tkgfp-expressing HSV-1 amplicon vectors showing colocalization of both components of the tkgfp fusion construct (Fig. 2B).

The outcome as measured by tumor volume showed 50% partial and 18% complete responses. To assess the gene therapeutic effect by standard volumetric assay, 22 nude mice with human Gli36dEGFR gliomas were transduced in vivo with HSV-1-cdlREStk39gfp amplicon vectors and subjected to prodrug therapy with ganciclovir and 5-fluorocytosine. Growth slopes of tumors were determined and used to assess response to therapy (Fig. 3A). All 22 positive control tumors stably expressing cd and tk39gfp were successfully treated with prodrugs leading to disappearance of tumors within 10 days (Fig. 3B). Of 22 in vivo transduced tumors, 4 tumors disappeared completely during prodrug therapy (complete responders). Eleven other in vivo transduced tumors showed a decelerated growth compared with the negative control tumors in the respective same animals (partial responders, growth of 28 ± 16% compared with negative controls). This represents a response rate of 15 of 22 (68%) in vivo transduced tumors (Fig. 3B). Growth slopes of tumors responding to gene therapy differed significantly from those of negative control tumors ($t$ test, $P < 0.05$). Seven of 22 in vivo transduced tumors did not respond to prodrug therapy.

$[^{18}F]$FLT-PET is able to assess tumor response after 1 week of prodrug therapy. To assess the effects of gene therapy on tumor proliferation, $[^{18}F]$FLT-PET was done before and after therapy to monitor response to therapy with regard to proliferative

![Figure 4](image-url). Protocol for imaging-guided gene therapy using MRI, $[^{18}F]$FLT-PET, and $[^{18}F]$FHBG-PET. Row 1 (MRI) and row 2 ($[^{18}F]$FLT-PET) display tumor morphology and proliferative activity before transduction; row 3 ($[^{18}F]$FHBG-PET) illustrates the intensity of exogenous gene expression after in vivo transduction; and rows 4 and 5 show early and late $[^{18}F]$FLT-PET follow-up under therapy. The negative control tumor shows no expression of HSV-1-tk and an increase in size and proliferative activity in the course of therapy; the in vivo transduced tumor with a distinct tk expression in $[^{18}F]$FHBG-PET, as well as the positive control tumor, disappears under therapy.
activity. Due to the complexity of the protocol, the complete series of MRI and PET studies as depicted in Fig. 4 could be obtained in 11 of 22 (50%) animals only. Significant differences in $^{[18}F$]FLT accumulation before (3.38 ± 3.65% ID/g) and after therapy (0.06 ± 0.19% ID/g; paired $t$ test, $P = 0.01$) were obtained in all stably cdIREStk39gfp expressing positive control tumors (Figs. 4–6). Eight of 11 in vivo transduced tumors responded to gene therapy as visualized by $^{[18}F$]FLT-PET. At the same time, the positive control tumor disappeared.

For all tumors, volumetric data did not correspond directly to $^{[18}F$]FLT-PET and $^{[18}F$]FHBG-PET as some tumors showed a partial response, as indicated by $^{[18}F$]FLT-PET, with no reduction in overall tumor volume (Figs. 5 and 6C). A positive correlation ($R = 0.83$) was found between volumetric data and $^{[18}F$]FLT-PET in the subsets of tumors that responded to therapy as complete responders (Fig. 6C). Figure 6C also indicates a positive relation between the change in FLT uptake and volumetry in nonresponding tumors ($R = 0.57$). It should be pointed out that 22 mice have been studied in the same study protocol. Volumetric data were obtained in all animals; the full set of imaging data could only be obtained in 11 of these 22 animals. The correlations between FLT-PET and FHBG-PET (Fig. 6E), as well as between FLT-PET and volumetry (Fig. 6C), are based on these 11 animals.

**Discussion**

Gene therapy is one of the promising approaches for a targeted treatment of tumors. However, its efficiency in clinical application for patients with glioblastomas has been disappointing thus far and reported to occur only in small tumors. The most important hurdles for successful application of gene therapy in patients with glioblastomas are the heterogeneity of tumor tissue and the limited transduction efficiency of current vectors. In this study, we therefore aimed at the further characterization of these two limiting factors by (i) identification of viable target tissue that might benefit from gene therapy and (ii) quantification of the transduction efficiency, both assessed noninvasively by PET. The imaging protocol used was aimed to reflect the procedures that would be done in a clinical situation. First, MRI was used for exact tumor localization. Then, markers for endogenous gene expression, such as FDG and FLT for the expression of glucose and nucleoside transporters, as well as for the expression of cellular hexokinase and thymidine kinase genes, respectively, and MET for the expression of amino acid transporters, were used to identify the actively proliferating tumor tissue. In addition, these tracers can be used as surrogate markers for cellular density (FDG), neovascularization (MET), and proliferative activity (FLT). FLT was also used to determine the gene therapy–induced inhibition of proliferative activity of the tumor. A marker for exogenously introduced therapeutic gene expression (FHBG) could localize the transduced tissue dose of therapeutic gene expression. Using this “imaging-guided” gene therapy protocol, we found a response rate of 68% of the in vivo transduced tumors with 18% complete responders as deduced from tumor volumetry. Most importantly, the primary transduction efficiency as measured by FHBG-PET could be correlated with the induced therapeutic effect, although follow-up imaging data by use of FLT-PET could only be obtained in 50% of investigated animals due to the complexity of the protocol. In tumors that responded to therapy, the decrease in FLT uptake corresponded to the decrease in tumor volume.

Several clinical gene therapy trials have outlined the promises as well as the difficulties associated with gene therapy. Suicide gene therapy for patients with recurrent glioblastoma using the HSV-1-TK/ganciclovir system has been done using retroviral (11, 14), adenoviral (29, 30), and HSV-1 (10, 13) vectors. Usually, imaging follow-up in those studies is done by gadolinium-enhanced MRI bearing the difficulty of assessing residual active tumor tissue after therapy and differentiating it from treatment-induced enhancement. Overall, it has been shown that suicide gene therapy has

**Figure 5.** Response to gene therapy of an in vivo transduced tumor (cross marker) and a positive control tumor (neck) as imaged by $^{[18}F$]FLT-PET. $^{[18}F$]FLT-PET after administration of prodrugs shows a circumscribed area lacking radiotracer uptake colocalizing to the transduced portion of the tumor as visualized by $^{[18}F$]FHBG-PET. At the same time, the positive control tumor ($^{[18}F$]FLT-PET (Fig. 6) and a positive control tumor ($^{[18}F$]FHBG-PET correlated with the resulting therapeutic efficiency as measured by the difference of $^{[18}F$]FLT accumulation before and after therapy ($R = 0.73; P < 0.01$; Fig. 6B).
potential therapeutic efficacy, which nevertheless remains either partial or occurs only in single patients with small tumors. Explanations for the limited therapeutic efficiency include the heterogeneity of target tissue (31), insufficient transduction efficiency (32), and interindividual variability of infectivity by vector particles due to different entry receptor status (8). Ongoing research focuses on the development of safe replication-conditional vectors and genetic approaches to target vascular and growth factor receptors and transforming growth factor-β, as well as to stimulate the immune response. All of these approaches rely on the noninvasive visualization of the target to allow an efficient targeted application of vectors and therapeutic genetic material and to allow a direct assessment of efficiency (15).

Some authors have reported noninvasive imaging follow-up of suicide gene therapy in experimental models, but these studies were usually done on tumors grown from stably transfected cell lines (33–36). Few studies used molecular imaging-guided follow-up after transduction of therapeutic genes in vivo using adenoviral (37, 38) and lentiviral vectors (39). To our knowledge, this is the first study of a HSV-1 ampiclon vector-mediated gene therapy approach that uses multimodal molecular imaging techniques for noninvasive follow-up in a glioma model.

HSV-1 has many properties that make it especially suitable as a vector to treat diseases affecting the CNS (i.e., its natural neurotropism, high transduction efficiency, large transgene capacity, and the ability of entering a latent state in neurons). Besides replication-conditional HSV-1 mutants, the “gutless” HSV-1 ampiclon vector has several properties, which make it a promising candidate gene transfer vehicle for clinical use (6, 40). No virus proteins are encoded; it is nearly nontoxic when packaged without contaminating helper virus; and it can infect most mammalian cell types and can accommodate large fragments of foreign DNA. Helper virus-free packaging systems use replication-competent, packaging-defective genomes of HSV-1 to provide the functions necessary for replication and packaging of cotransfected ampiclon DNA (5, 41, 42). The resulting stocks of helper virus-free HSV-1 ampiclons have been shown to be safe and efficient in culture and in vivo, and they transduce a variety of CNS-derived cells including human gliomas (4, 6, 7, 43, 44). Moreover, we have shown that vector-mediated gene expression mediated by replication-conditional and HSV-1 ampiclon vectors can be noninvasively assessed in vivo by PET (7, 28).

Noninvasive localization of exogenously introduced gene expression by PET relies on the transduction of “marker genes” along with the therapeutic genes. Radiolabeled 9-(4-18F-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) is a safe and efficient PET tracer to detect HSV-1-tk expression (26, 45). Mutant HSV-1 thymidine kinases have been developed that, compared with wild-type thymidine kinase, render cells more sensitive to specific nucleoside analogues like the prodrug ganciclovir used for therapy and the PET tracer [18F]FHBG used for imaging. We therefore used the

Figure 6. Response to therapy as assessed by [18F]FLT-PET. A, [18F]FLT accumulation (in %ID/g) after therapy compared with baseline accumulation is significantly decreased in stably transfected tumors. Eight of 11 in vivo transduced tumors showed a significant decrease in [18F]FLT accumulation after therapy (\( P < 0.05; \*, P < 0.01\)). Bars, SD. B, correlation between the intensity of cdHER3tk expression, which is equivalent to transduction efficiency, and tissue dose of vector-mediated therapeutic gene expression, as measured by [18F]FHBG-PET (in %ID/g), and the induced therapeutic effect as measured by [18F]FLT-PET (\( R = 0.73, P < 0.01\)). Therapeutic effect (\( \Delta \) [18F]FLT) was calculated as the difference between [18F]FLT accumulation after and before therapy. C, relation between changes in volumetry and FLT uptake. Changes in tumor volume and FLT uptake were plotted for all tumors grown in 11 animals where the full imaging protocol could be completed. There is a strong correlation between volumetry and change in FLT uptake (\( R = 0.83\)) for those tumors responding to therapy (complete responders) and a weaker correlation (\( R = 0.57\)) for those tumors not responding to therapy (nonresponders). No correlation was found for those tumors where focal alterations of FLT uptake occurred, which did not lead to a reduction in overall tumor volume (partial responders).
mutated thymidine kinase HSV-1-tk39 (7, 46) to serve as a PET marker gene and as a therapeutic gene at the same time.

To enhance the antitumoral effects of our construct, we used two therapeutic genes, *Escherichia coli* cd and HSV-1-tk39, which confer sensitivity to the prodrugs 5-fluorocytosine and ganciclovir, respectively. TK39 phosphorylates the nontoxic prodrug ganciclovir, which then becomes phosphorylated by endogenous kinases to ganciclovir-triphosphate, causing chain termination and single-strand breaks on incorporation into DNA (47). Moreover, not only cells expressing the transgene but also neighboring nontransduced tumor cells can undergo cell death by bystander killing (48). CD deaminates the nontoxic pyrimidine 5-fluorocytosine to the cytotoxic 5-fluorouracil (5-FU). 5-FU is processed both to the ribonucleotide 5-fluorouracil triphosphate, which is incorporated into RNA and interferes with RNA processing, and to 5-fluoro-2-deoxyuridine-5-monophosphate, which irreversibly inhibits thymidylate synthase and interferes with DNA synthesis (49). TK/ ganciclovir– and CD/5-fluorocytosine–induced apoptosis converge at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins (50). The combination of those two therapeutic genes has been shown to have synergistic effects in glioma cells (20, 51, 52), although Moriuchi et al. (53) critically proposed a mutual counteraction. Previously, we have shown for our cd/IRES/tk39gfp construct a proportional coexpression of cd and tk39gfp and did not observe an attenuation of the killing of glioma cells for this combination (7).

To localize and distinguish the viable tissue of the tumors and to observe their response to therapy, the clinical PET marker for tumor proliferation, [18F]FLT, was used. [18F]FLT has recently been introduced as a PET tracer for tumor imaging (54–56). 3'-Deoxy-3'-fluorothymidine (FLT) is a nucleoside analogue and is phosphorylated to 3'-fluorothymidine monophosphate (FLT-MP) through the S phase–specific enzyme TK-1. Phosphorylation of FLT accurately reflects changes in TK-1 enzyme activity (57). This phosphorylation leads to an intracellular trapping of FLT-MP, which is a prerequisite for its use as a PET tracer. The [18F]FLT uptake has been shown to correlate to proliferation in vivo as measured by Ki67 proliferation index (58). Besides its application for various other tumor types, [18F]FLT-PET has also recently proved useful for evaluating tumor grade and cellular proliferation in brain tumors (59–61). [18F]FLT is especially suitable for therapy follow-up, as it reflects early effects of anticancer therapy (62). In tumors that responded to gene therapy, we found [18F]FLT accumulation to decrease already within a few days after initiation of prodrug application (Figs. 4–6). A corresponding reduction in tumor volume was found (Fig. 6C). It should be pointed out that [18F]FLT-PET revealed additional, complementary information about tumor progression than volumetry. Some tumors that increased in volume during the course of treatment showed decreasing proliferation as measured by [18F]FLT accumulation in follow-up studies. This decreased proliferative activity was always observed in the part of the glioma where in vivo transduction had taken place, which was visualized as HSV-1-tk39 expression by [18F]FHBG-PET, whereas the rim of the tumor usually showed a higher proliferative activity (Fig. 5). Quantification of [18F]FLT accumulation was done in the same area where in vivo transduction has been observed by [18F]FHBG-PET. A prerequisite for this was the exact coregistration of [18F]FHBG-PET and [18F]FLT-PET images using a newly in-house developed software for fast coregistration of multimodal image data sets (VINCI; ref. 25).

Because we used a replication-deficient ampiclon vector that could transduce tumor cells only at the injection site, the therapeutic response in larger tumors was therefore restricted to that injection site also. Thus, the transduced therapeutic gene caused a local regression of tumor proliferation, which was not sufficient to stop proliferation of the entire tumor. These findings are supported by the correlation between level of CD-IRES-TK39-GFP expression as measured by [18F]FHBG-PET and therapeutic efficiency as measured by [18F]FLT-PET (Fig. 6B).

In summary, we conclude that the identification of target tissue enables targeted vector application, which will be an essential tool in clinical applications. Determination of the tissue dose of vector-mediated gene expression is feasible and enables a correlation to the induced therapeutic effect. This type of multimodal imaging protocol, together with improved vector and promoter technology (63, 64) for tumor-specific targeting, will be of great importance for the further development of clinical gene therapy trials, as an ineffective transduction and low tissue dose of therapeutic gene can be noted early, which may guide the further management of the patient to avoid that he is treated in vain. This type of imaging-guided gene therapy protocol will therefore facilitate the development of safe and efficient gene therapy protocols for clinical application.

### Acknowledgments

Received 7/3/2006; revised 9/12/2006; accepted 10/23/2006.

**Grant support:** Deutsche Forschungsgemeinschaft (DFG-Ja98/1-2), Ministerium für Schule, Wissenschaft und Forschung NRW (MSWF 516-40000299), Center for Molecular Medicine Cologne (CMMC-TV46), and 6th FW EU grant EMIL (LSHC-CT-2004-503569).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

### References


11. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and...
radiation in adults with previously untreated glioblas-
12. Ram Z, Culver KW, Oshiro EM, et al. Therapy of
malignant brain tumors by intratumoral implantation
of retroviral vector-producing cells. Nat Med 1997;3:
1354–61.
Toxicity evaluation of replication-competent herpes
simplex virus (ICP 34.5 null mutant 1719) in patients
with recurrent malignant glioma. Gene Ther 2000;7:
859–66.
clinical trial of gene therapy for recurrent glioblastoma
multiforme by tumor transduction with the herpes
simplex thymidine kinase gene followed by ganclovir.
GLI28European-Canadian Study Group. Hum Gene
tomography of vector-mediated gene expression in
the expression of transduced genes in vivo. Cancer Res
approach to evaluation of the non-invasive imaging of transgenes
using cis-linked herpes simplex virus thymidine kinase.
target gene expression by imaging reporter gene
expression of HSV-1 thymidine kinase and green
fluorescent protein: implications for noninvasive imag-
20. Aghi M, Kramm CM, Chou TC, Breakfield XO, Chiocca EA. Synergistic anticancer effects of ganciclo-
vir/thymidine kinase and 5-fluorocytosine/cytosine
phosphokineticdosimetry of[(18)F]FHBG: an imaging model of pro-
clusive of 2-fluoro-2-deoxyglucose transport and
phosphorylation in rat hepatoma during gene therapy
noninvasive molecular imaging model of prostrate
castr gene suicide gene therapy using positron emis-
22. Soling A, Theiss C, Jungmichel S, Rainov NG. A dual
function fusion of herpes simplex virus type 1
thymidine kinase and firefly luciferase for noninvasive
in vivo imaging of gene therapy in malignant glioma.
the high level expression of human glioma cells. Hum Gene
in vivo of [18F]FLT uptake after chemotherapy: an
imaging study of adenoviral delivery of the HSV-tk gene
and ganciclovir administration in patients with current
therapy of patients with glioma. J Neurooncol 2003;65:
291–305.
27. Harsh GR, Drisboeck TS, Louis DN, et al. Thymidine
kinase activation in ganciclovir-mediated suicide mol-
gnant gliomas: a gene-marking and neurophathological study.
of [18F]fluoro-L-thymidine transport and phosphorylation
in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther
approach to evaluation of the non-invasive imaging of transgenes
using cis-linked herpes simplex virus thymidine kinase.
approach to evaluation of the non-invasive imaging of transgenes
using cis-linked herpes simplex virus thymidine kinase.
tomography of vector-mediated gene expression in
the expression of transduced genes in vivo. Cancer Res
33. Tjvajer JG, Joshi A, Callegari J, et al. A general
approach to evaluation of the non-invasive imaging of transgenes
using cis-linked herpes simplex virus thymidine kinase.
target gene expression by imaging reporter gene
expression of HSV-1 thymidine kinase and green
fluorescent protein: implications for noninvasive imag-
36. Aghi M, Kramm CM, Chou TC, Breakfield XO, Chiocca EA. Synergistic anticancer effects of ganciclo-
vir/thymidine kinase and 5-fluorocytosine/cytosine
phosphokinetic dosimetry of [(18)F]FHBG: an imaging model of pro-
clusive of 2-fluoro-2-deoxyglucose transport and
phosphorylation in rat hepatoma during gene therapy
noninvasive molecular imaging model of prostrate
castr gene suicide gene therapy using positron emis-
38. Soling A, Theiss C, Jungmichel S, Rainov NG. A dual
function fusion of herpes simplex virus type 1
thymidine kinase and firefly luciferase for noninvasive
in vivo imaging of gene therapy in malignant glioma.
the high level expression of human glioma cells. Hum Gene
41. Mier W, Haberkorn U, Eisenhart M. [18F]FLT; portrait
in vivo of [18F]FLT uptake after chemotherapy: an
imaging study of adenoviral delivery of the HSV-tk gene
and ganciclovir administration in patients with current
therapy of patients with glioma. J Neurooncol 2003;65:
291–305.
43. Harsh GR, Drisboeck TS, Louis DN, et al. Thymidine
kinase activation in ganciclovir-mediated suicide mol-
gnant gliomas: a gene-marking and neurophathological study.
of [18F]fluoro-L-thymidine transport and phosphorylation
in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther
45. Tjvajer JG, Joshi A, Callegari J, et al. A general
approach to evaluation of the non-invasive imaging of transgenes
using cis-linked herpes simplex virus thymidine kinase.
46. Aghi M, Kramm CM, Chou TC, Breakfield XO, Chiocca EA. Synergistic anticancer effects of ganciclo-
vir/thymidine kinase and 5-fluorocytosine/cytosine
phosphokinetic dosimetry of [(18)F]FHBG: an imaging model of pro-
clusive of 2-fluoro-2-deoxyglucose transport and
phosphorylation in rat hepatoma during gene therapy
noninvasive molecular imaging model of prostrate
castr gene suicide gene therapy using positron emis-
function fusion of herpes simplex virus type 1
thymidine kinase and firefly luciferase for noninvasive
in vivo imaging of gene therapy in malignant glioma.
the high level expression of human glioma cells. Hum Gene
Imaging-Guided Gene Therapy of Experimental Gliomas

Andreas H. Jacobs, Maria Adele Rueger, Alexandra Winkeler, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/4/1706

Cited articles
This article cites 61 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/4/1706.full#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/67/4/1706.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/67/4/1706.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.